Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-12-31

FDA Approved: GABAPENTIN — Supplemental Application (ScieGen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for gabapentin by ScieGen Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gabapentin (Gabapentin)

Snippet

SUPPL AP for GABAPENTIN (GABAPENTIN)